Sarepta (SRPT) Sees Modest Selling Amid $225M Stock Offering

September 21, 2016 4:06 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) is down just 0.7% on plans to offer $225 million in common stock. The stock has more than doubled this week after announcing FDA approval.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings, Momentum Movers, Trader Talk

Add Your Comment